================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: February 21, 2003
QLT Inc.
-----------------------------------------------------
(Exact name of registrant as specified in its Charter)
British Columbia, Canada 000-17082 N/A
- ------------------------ ------------------------ -------------------
(Jurisdiction of (Commission File Number) (IRS Employer
Incorporation) Identification No.)
QLT Inc.,
887 Great Northern Way,
Vancouver, B.C., CANADA, V5T 4T5
(604) 707-7000
----------------------------------------------------
(Address, including zip code, and telephone number,
including area code, of principal executive offices)
================================================================================
ITEM 5. OTHER EVENTS
On February 21, 2003, QLT Inc. announced that enrollment of
additional patients in its ongoing phase III studies of
tariquidar in non-small cell lung cancer patients was being
suspended for approximately three months pending the
completion of the planned interim safety and efficacy analysis
by an Independent Data and Safety Monitoring Committee (DSMC),
upon the recommendation of the DSMC. The DSMC made its
recommendation in part due to some safety concerns respecting
the levels of toxicity seen in the tariquidar arms of the two
trials. Enrollment in the two studies had already reached the
threshold number of patients required for the three month
safety and efficacy interim analysis. The DSMC has not yet
seen efficacy data. The interim analysis for the two studies,
which will include efficacy data, is expected to be conducted
in May 2003 for the TLC1 trial, and June of 2003 for the TLC2
trial. The DSMC unanimously recommended that the two trials
remain blinded in order to preserve the integrity of the
trials.
ITEM 7. EXHIBITS
Exhibit
Number Description
- ------- -----------
99.1 Press release dated February 21, 2003
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
QLT Inc.
---------------------------------
(Registrant)
Date February 21, 2003 /s/ Paul J. Hastings
----------------- -------------------------------------
(Signature)
President and Chief Executive Officer